Combined IL-21 and Low-Dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model

BACKGROUND: In vivo studies have recently demonstrated that interleukin 21 (IL-21) enhances the anti-tumor function of T-cells and NK cells in murine tumor models, and the combined use of IL-21 and IL-15 has resulted in prolonged tumor regression and survival in mice with previously established tumo...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Hong, Wisner, Preya, Yang, Guojun, Hu, Hong-Ming, Haley, Dan, Miller, William, O'Hara, Aisling, Alvord, W Gregory, Clegg, Christopher H, Fox, Bernard A, Urba, Walter J, Walker, Edwin B
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1502139/
https://www.ncbi.nlm.nih.gov/pubmed/16772043
http://dx.doi.org/10.1186/1479-5876-4-24

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1502139/
https://www.ncbi.nlm.nih.gov/pubmed/16772043
http://dx.doi.org/10.1186/1479-5876-4-24

Ejemplares similares